Recruitment

Recruitment Status
Completed

Inclusion Criteria

Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
No history of periodontal therapy in preceding last 6 months
No use of antibiotics in the preceding 6 months
Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
No history of periodontal therapy in preceding last 6 months
No use of antibiotics in the preceding 6 months

Exclusion Criteria

Alcoholics
Pregnant or lactating females
Subjects with aggressive periodontitis,
...
Alcoholics
Pregnant or lactating females
Subjects with aggressive periodontitis,
Immunocompromised subjects
Those on systemic ALN/bisphosphonate therapy
Use of smokeless tobacco in any form,
Subjects with known systemic disease
Known or suspected allergy to the ALN/bisphosphonate group

Summary

Conditions
Chronic Periodontitis
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 30 years and 50 years
Gender
Both males and females

Inclusion Criteria

Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
No history of periodontal therapy in preceding last 6 months
No use of antibiotics in the preceding 6 months
Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
No history of periodontal therapy in preceding last 6 months
No use of antibiotics in the preceding 6 months

Exclusion Criteria

Alcoholics
Pregnant or lactating females
Subjects with aggressive periodontitis,
...
Alcoholics
Pregnant or lactating females
Subjects with aggressive periodontitis,
Immunocompromised subjects
Those on systemic ALN/bisphosphonate therapy
Use of smokeless tobacco in any form,
Subjects with known systemic disease
Known or suspected allergy to the ALN/bisphosphonate group

Tracking Information

NCT #
NCT02168543
Collaborators
Not Provided
Investigators
  • Principal Investigator: Dr. Anuj Sharma, BDS, MDS RIMS, Ranchi
  • Dr. Anuj Sharma, BDS, MDS RIMS, Ranchi